FDA Approval of Aduhelm (aducanumab) For Alzheimer’s Disease

Regarding FDA-Approved Alzheimer’s Disease Drug Aduhelm (aducanumab):

JWM Neurology anticipates prescribing and administering the drug Aduhelm (aducanumab) to appropriate patients within next the few months. Appropriate patients could potentially be individuals with a diagnosis of Mild Cognitive Impairment or mild stage dementia due to Alzheimer’s disease, who meet further criteria for safe administration of the medication based on FDA guidelines and detailed clinician evaluation.

If you are currently a JWM Neurology patient and are interested in Aducanumab, you can consult with your JWM provider. This medication is a long-term treatment, most likely requiring insurance authorization, and may require additional testing to confirm eligibility.

If you are not currently a JWM Neurology patient and are interested in being evaluated for Aduhelm (aducanumab), please ask your current healthcare provider to send a referral and your medical records to JWM Neurology via fax to 317-576-6311. Alternatively, you may call 317-308.2800 (toll-free: 800-801-0262) to schedule an appointment.

You can view information about Aduhelm (aducanumab) on the FDA website.